Cita APA

Palazon-Carrion, N., Garcia-Sancho, A., Nogales-Fernandez, E., Jimenez-Cortegana, C., Carnicero-Gonzalez, F., Rios-Herranz, E., . . . de la Cruz-Merino, L. (2022). Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.

Citación estilo Chicago

Palazon-Carrion, N., et al. Lenalidomide Plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. 2022.

Cita MLA

Palazon-Carrion, N., et al. Lenalidomide Plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. 2022.